PLUS THERAPEUTICS INC PSTV 深 滬
已收盤 07-31 16:00:00 美东时间
3.87
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.87
- 總市值 2664.07万
- 52周最高 23.425
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.90
- 委 比 0.00%
- 總股本 688.39万
- 歷史最高 8583.75
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.225
- 每 手 1
- 風險率 4.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cerenome Launches as an Integrated CNS Oncology Company
Cerenome (formerly Plus Therapeutics) rebrands as an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and AI to improve CNS cancer detection, treatment, and understanding. Effective August 3, 2026, the company will trade under the ticker symbol "CNSY." Its strategy centers on three platforms: CNSide® diagnostics, REYOBIQ™ radiotherapeutic, and an AI-driven data platform, aiming to enhance patient outcomes a...
07-31 12:30
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provi...
07-21 19:35
Plus Therapeutics Highlights Updated NCCN CNS Cancer Guidelines Reinforcing CSF Analysis In Leptomeningeal Metastases Care
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a ser...
07-14 19:34
Plus Therapeutics wins Elevance Health coverage deal
Plus Therapeutics (PSTV) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with Elevance Health (ELV) to expand coverage for a cancer screening test...
06-25 20:02
CNSide Diagnostics Strikes Deal With Elevance Health To Offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay, Effective May 1, 2026
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE:ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the Unit...
06-25 19:35
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Plus Therapeutics will host a business update conference call on June 30, 2026, at 8:30 a.m. ET, discussing progress on its CNS cancer diagnostics, lead drug Reyobiq, and integrated AI plans. CEO Marc H. Hedrick highlights advancements in diagnostics, therapeutics, and AI, aiming to improve outcomes for CNS oncology patients and deliver long-term value to shareholders. The call will also cover the CNSide diagnostic launch and the company's vision...
06-23 11:30
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
06-08 21:52
